Baricitinib shows promise in treating Alopecia areata,finds study

For the study design, patients were randomized 1:1:1:1 to receive placebo, baricitinib 1-mg, 2-mg, or 4- 66 mg once daily. Two consecutive interim analyses were performed after all patients completed 67 Weeks 12 and 36 or had discontinued treatment prior to these time points. The primary 68 endpoint was the proportion of patients achieving Severity of Alopecia Tool (SALT) score 69 ≤20 at Week 36. Logistic regression was used with nonresponder imputation for missing 70 data.

Results highlighted some important facts.

• A total of 110 patients were randomized (placebo: 28; baricitinib 1-mg: 28; 2-mg: 72 27; 4-mg: 27). Baricitinib 1-mg dose was dropped after the first interim analysis based on 73 lower SALT30 response rate.
• At Week 36, the proportion of patients achieving SALT score 74 ≤20 was significantly greater in baricitinib 2-mg (33.3%, p=0.016) and 4-mg (51.9%, 75 p=0.001) groups versus placebo (3.6%). Baricitinib was well tolerated with no new safety 76 findings.

" In conclusion, these results suggest that once-daily baricitinib is effective for patients with 293 ≥50% scalp hair loss and supports the rationale for the Phase 3 program currently underway. 294 Additional long-term data from the Phase 3 trial will be reported once available."the team confirmed.

· For full article follow the link: 10.1016/j.jaad.2021.05.050

Source: Journal of the American Academy of Dermatology